Kymab, a human monoclonal antibody biopharmaceutical group, has appointed Sonia Quaratino as its first Chief Medical Officer.
Quaratino will manage the clinical development of the Group's expanding therapeutic antibody portfolio.
Quaratino is an immunologist and joins Kymab from Novartis, where she has served as Global Clinical Program Leader – Transitional Clinical Oncology, responsible for the clinical development of proprietary therapeutic antibody programmes in immuno-oncology.
Prior to her role with Novartis, Quaratino was Senior Medical Director and Immunology Advisor at Merck Serono, where she was responsible for the clinical development of various immunomodulators.
Quaratino also has over 20 years of professional experience in biomedical research in UK academic institutions including Imperial College London and the University of Southampton.
Quaratino has an extensive professional background that includes a Medical Degree and a Doctorate in Haematology-Oncology from the University of Palermo, Italy and a PhD in Immunology from Imperial College London, UK.
For a number of years, she was a Professor of Immunology at the University of Southampton. During her time in Southampton, her focus was on the pathogenic mechanisms underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.
